ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,001 to 3,020 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)54 of 1,206

49 of 1,220

0.5 points

-1.2 to 2.1

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization185 of 1,206

141 of 1,220

3.8 points

1.1 to 6.5

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)104 of 1,206

65 of 1,220

3.3 points

1.3 to 5.4

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI181 of 1,206

159 of 1,220

2.0 points

-0.8 to 4.7

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)200 of 1,206

153 of 1,220

4.0 points

1.2 to 6.9

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)107 of 1,206

65 of 1,220

3.5 points

1.5 to 5.6

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)82 of 1,206

66 of 1,220

1.4 points

-0.5 to 3.3

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI)145 of 1,206

119 of 1,220

2.3 points

-0.2 to 4.8

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)281 of 1,206

239 of 1,220

3.7 points

0.4 to 7.0

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR80 of 1,206

65 of 1,220

1.3 points

-0.6 to 3.2

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)246 of 1,206

203 of 1,220

3.8 points

0.7 to 6.8

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)126 of 1,206

94 of 1,220

2.7 points

0.5 to 5.0

2,426NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)217 of 1,206

178 of 1,220

3.4 points

0.5 to 6.3

2,426NCT02173379

Absorb IV Randomized Controlled Trial

FluLaval™ Quadrivalent Group vs Fluzone® Quadrivalent Group: serious adverse events5 of 1,207

4 of 1,217

0.1 points

-0.5 to 0.7

2,424NCT02242643

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

Early ART vs Deferred ART: Transmission Risk Behavior Outcome 1156 of 1,236

155 of 1,187

-0.4 points

-3.1 to 2.2

2,423NCT00867048

Strategic Timing of Antiretroviral Treatment

Vitamin D (Cholecalciferol) vs Placebo: deaths from any cause5 of 1,211

5 of 1,212

0.0 points

-0.6 to 0.6

2,423NCT01942694

Vitamin D and Type 2 Diabetes Study

Vitamin D (Cholecalciferol) vs Placebo: Time to Development of Diabetes293 of 1,211

323 of 1,212

-2.5 points

-5.9 to 1.0

2,423NCT01942694

Vitamin D and Type 2 Diabetes Study

Vitamin D (Cholecalciferol) vs Placebo: serious adverse events173 of 1,211

153 of 1,212

1.7 points

-1.1 to 4.4

2,423NCT01942694

Vitamin D and Type 2 Diabetes Study

BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: Time to First Severe Asthma Exacerbation, Treatment Policy Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years)64 of 1,209

114 of 1,212

-4.1 points

-6.2 to -2.0

2,421NCT05505734

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years)62 of 1,209

110 of 1,212

-3.9 points

-6.0 to -1.9

2,421NCT05505734

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=151"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=151

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02173379-263b6dc5",
        "title": "Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)",
        "summary": "54 of 1206 against 49 of 1220; risk difference 0.5 points, 95% interval -1.2 to 2.1; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-263b6dc5",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2426,
        "risk_difference": {
          "value": 0.004612184976755564,
          "lower": -0.011612378938061333,
          "upper": 0.020954656285816768
        },
        "group_1": "54 of 1,206",
        "group_2": "49 of 1,220",
        "difference": "0.5 points",
        "interval": "-1.2 to 2.1",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      },
      {
        "id": "NCT02173379-4d3e90dc",
        "title": "Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization",
        "summary": "185 of 1206 against 141 of 1220; risk difference 3.8 points, 95% interval 1.1 to 6.5; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-4d3e90dc",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2426,
        "risk_difference": {
          "value": 0.03782589783323817,
          "lower": 0.01067639062632417,
          "upper": 0.06502822535423161
        },
        "group_1": "185 of 1,206",
        "group_2": "141 of 1,220",
        "difference": "3.8 points",
        "interval": "1.1 to 6.5",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=152",
  "request_id": "kiuUnZS05I-BtJuW"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?